According to Glenmark, the drug is intended for rhinitis in adults and pediatric patients 12 years and older in the United States.
“The FDA approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to deliver innovative treatment options in our key therapeutic areas. said the commercial director
Ryaltris will be marketed and distributed in America by Hikma Specialty USA, Inc., under its exclusive license agreement with Glenmark Specialty SA
Glenmark has entered into commercial agreements with several partners around the world, including Menarini for the commercialization of Ryaltris in certain European markets, and with Bausch Health in Canada (where it is under review by Health Canada), the company said. .
Three out of four COVID-19 deaths in Delhi are unvaccinated patients
Tesla to start accepting dogecoins for merchandise, Musk tweets